1ICF

CRYSTAL STRUCTURE OF MHC CLASS II ASSOCIATED P41 II FRAGMENT IN COMPLEX WITH CATHEPSIN L

Summary for 1ICF

• Entry DOI: 10.2210/pdb1icf/pdb
• Descriptor: PROTEIN (CATHEPSIN L: HEAVY CHAIN), PROTEIN (CATHEPSIN L: LIGHT CHAIN), PROTEIN (INVARIANT CHAIN), ... (5 entities in total)
• Functional Keywords: cysteine proteinase, cathepsin, mhc class ii, invariant chain, thyroglobulin type-1 domain, hydrolase
• Biological source: Homo sapiens (human); More
• Total number of polymer chains: 6
• Total formula weight: 62721.42

Authors

Guncar, G.,Pungercic, G.,Klemencic, I.,Turk, V.,Turk, D. (deposition date: 1999-01-07, release date: 2000-01-12, Last modification date: 2024-10-30)

Primary citation

Guncar, G.,Pungercic, G.,Klemencic, I.,Turk, V.,Turk, D.
Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S.
EMBO J., 18:793-803, 1999

PubMed Abstract: The lysosomal cysteine proteases cathepsins S and L play crucial roles in the degradation of the invariant chain during maturation of MHC class II molecules and antigen processing. The p41 form of the invariant chain includes a fragment which specifically inhibits cathepsin L but not S. The crystal structure of the p41 fragment, a homologue of the thyroglobulin type-1 domains, has been determined at 2.0 A resolution in complex with cathepsin L. The structure of the p41 fragment demonstrates a novel fold, consisting of two subdomains, each stabilized by disulfide bridges. The first subdomain is an alpha-helix-beta-strand arrangement, whereas the second subdomain has a predominantly beta-strand arrangement. The wedge shape and three-loop arrangement of the p41 fragment bound to the active site cleft of cathepsin L are reminiscent of the inhibitory edge of cystatins, thus demonstrating the first example of convergent evolution observed in cysteine protease inhibitors. However, the different fold of the p41 fragment results in additional contacts with the top of the R-domain of the enzymes, which defines the specificity-determining S2 and S1' substrate-binding sites. This enables inhibitors based on the thyroglobulin type-1 domain fold, in contrast to the rather non-selective cystatins, to exhibit specificity for their target enzymes.

PubMed: 10022822
DOI: 10.1093/emboj/18.4.793

Experimental method

X-RAY DIFFRACTION (2 Å)